DM Healthcare Investment

Asia Regenerative Medicine (Hong Kong) Limited Successfully Closes Seed Round

February 1, 2024

SHATIN, Hong Kong, Feb. 1, 2024 -- Asia Regenerative (Hong Kong) Limited (also known as AHK) is pleased to announce that it successfully concluded its seed round raise of 8M HKD.

AHK is the premier provider for intelligent solutions along the therapeutic and research value chain. It's first-of-it’s-kind AI Cell Sorter pairs with the AI imager and smart bioreactor to drive therapeutic innovation, improve diagnostic precision, and enhance patient care outcomes. AHK is made in Hong Kong, and supported by the Hong Kong government to bring its integrated AI solutions to researchers, academics, and healthcare providers. 

Congratulations to the AHK team, and we look forward to seeing what the team achieves moving forward.